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Background In the ENGAGE AF-TIMI 48 trial, the higher-dose edoxaban (HDE) regimen had a similar incidence of ischaemic stroke
compared with warfarin, whereas a higher incidence was observed with the lower-dose regimen (LDE). Amiodarone
increases edoxaban plasma levels via P-glycoprotein inhibition. The current pre-specified exploratory analysis was
performed to determine the effect of amiodarone on the relative efficacy and safety profile of edoxaban.
Methods and
results
At randomization, 2492 patients (11.8%) were receiving amiodarone. The primary efficacyendpoint of stroke or systemic
embolic eventwas significantly lowerwithLDEcomparedwith warfarin in amiodarone treated patients vs. patientsnoton
amiodarone (hazard ratio [HR] 0.60, 95% confidence intervals [CIs] 0.36–0.99 and HR 1.20, 95% CI 1.03–1.40, respect-
ively; P interaction,0.01). In patients randomized to HDE, no such interaction for efficacy was observed (HR 0.73, 95%
CI 0.46–1.17 vs. HR 0.89, 95% CI 0.75–1.05, P interaction ¼ 0.446). Major bleeding was similar in patients on LDE (HR
0.35, 95% CI 0.21–0.59 vs. HR 0.53, 95% CI 0.46–0.61, P interaction ¼ 0.131) and HDE (HR 0.94, 95% CI 0.65–1.38 vs.
HR 0.79, 95% CI 0.69–0.90, P interaction ¼ 0.392) when compared with warfarin, independent of amiodarone use.
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant
reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable
bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
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Introduction
In the effective anti-coagulation with factor Xa next generation in
atrial fibrillation (AF)–thrombolysis in myocardial infarction 48
(ENGAGE AF-TIMI 48) trial, two dosing regimens of the direct
factor Xa inhibitor edoxaban were found to be non-inferior to well-
managed warfarin for the prevention of stroke or systemic embolic
events (SEEs) in patientswith AF.1 In addition, both regimensof edox-
aban significantly reduced the risk of major bleeding and cardiovascu-
lar death when compared with warfarin. The lower-dose (LD)
regimen of edoxaban, however, was associated with a 41% relative
increase in ischaemic stroke when compared with warfarin.
Edoxaban acts as a substrate for the efflux transporter p-glycoprotein
(P-gp), locatedprimarily in the intestine,which limits systemic absorption
of drugs by pumping them back into the intestinal lumen.2–4 Edoxaban
underwent extensive preclinical testing to determine the optimal
dosing for patients co-treated with P-gp inhibitors. Co-administration
of edoxaban with strong P-gp inhibitors verapamil, quinidine, and drone-
darone significantly increased maximal edoxaban drug levels (Cmax), the
area under the curve, and trough (Cmin) plasma levels.
5 Based on these
findings, as well as on further modelling and simulation of edoxaban
exposure and response relationships,5 a 50% dose reduction was imple-
mented in the ENGAGE AF-TIMI 48 trial for patients taking these drugs.
In contrast, amiodarone is a weaker P-gp inhibitor; based on drug–drug
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interaction studies there was no dose reduction implemented in the
ENGAGE AF-TIMI 48 trial for concomitant amiodarone use.
Amiodarone is one of the most frequently used anti-arrhythmic
drugs in patients with AF, in spite of its pronounced side effect
profile as well as numerous drug–drug interactions.6 Amiodarone
decreases hepatic metabolism of warfarin by inhibiting cytochrome
P450-dependent elimination pathways, necessitating frequent dose
adjustments to counterbalance its potentiating effect on the degree
of anti-coagulation. In view of its widespread use, potential interac-
tions with non-vitamin K oral anti-coagulants (NOACs) such as
edoxaban are of great clinical importance for a large number of
patients. In the current pre-specified exploratory analysis, we evalu-
ated the efficacy and safety of edoxaban in patients co-treated with
amiodarone in the ENGAGE AF-TIMI 48 trial.1 Since a prior analysis
of edoxaban concentration in this trial demonstrated correlations
with clinical efficacy and safety,7 we also explored the impact of
concomitant amiodarone use on edoxaban concentration and
outcomes.
Methods
Study population and procedures
The design and main results of the phase 3 multinational, double-blind,
double-dummy, non-inferiority ENGAGE AF-TIMI 48 trial have
previously been reported.1,2 In brief, 21′105 patients with AF at
moderate-to-high risk of stroke were randomized to receive higher-dose
(HD) edoxaban (60 mg once daily), LD edoxaban (30 mg once daily), or
warfarin. In patients with an estimated creatinine clearance 30–50 mL/
min, body weight ≤60 kg, or in those requiring concomitant use of ver-
apamil, quinidine, or dronedarone, the edoxaban dose was reduced by
50% (HD edoxaban: 60–.30 mg; LD edoxaban 30 mg–.15 mg).
The ENGAGE AF-TIMI 48 trial was unique among the trials comparing
NOACs vs. warfarin in that dose reductions were performed not only
at randomization but also throughout the trial if a patient subsequently
met a criteria requiring dose reductions. Patients were eligible for inclu-
sion in ENGAGE AF-TIMI 48 if they were 21 years of age or older, had AF
documented within the 12 months prior to randomization, a CHADS2
score ≥2, and anti-coagulation therapy planned for the duration of the
trial.1 Most important exclusion criteria were AF due to a reversible
cause, severe renal insufficiency (creatinine clearance ,30 mL per
minute), a high risk of bleeding, use of dual anti-platelet therapy, and
moderate-to-severe mitral stenosis.2 Mean follow-up of the study was
2.8 years, which was the longest of all major NOAC trials.
Endpoints
Efficacy outcomes analysed included stroke or SEEs (the primary efficacy
endpoint), ischaemic stroke, haemorrhagic stroke, all-cause and cardio-
vascular mortality.1 Safety outcomes included International Society on
Thrombosis and Haemostasis8 major bleeding (principal safety end-
point), clinically relevant non-major bleeding, and intracranial haemor-
rhage.2 An independent clinical events committee blinded to randomized
treatment assignment adjudicated all events.
Statistical analysis
In the ENGAGE AF-TIM 48 study, the only randomization stratification
variables were CHADS2 score and dose adjustment.
1 For the current
analysis, the relative effect of edoxaban vs. warfarin in patients on amio-
darone at trial entry was compared the relative effect of edoxaban vs.
warfarin inpatientsnoton amiodarone. Hazard ratios (HRs) foredoxaban
and warfarin with 95% confidence intervals (CIs) stratified by amiodar-
one use at trial entry were calculated with the Cox proportional
hazards models (along with the randomization stratification factors of
CHADS2 score and dose adjustment status). We performed in addition
a multivariable sensitivity analysis to account for differences in baseline
characteristics across randomized treatment groups in patients taking
amiodarone as outlined in Table 1 (age ≥75 years, heart failure, and
hypertension).
Baseline characteristics are presentedasmedians (interquartile ranges) for
continuous variables and frequencies for categorical variables. Baseline
characteristics were compared with the Wilcoxon rank sum tests for con-
tinuous variables and x2 tests for categorical variables. Event rates were
expressed per 100 patient-years. Efficacy analyses were analysed in the
intention-to-treat study population and bleeding outcomes in the safety
population which included all patients who had received at least one
dose of study drug. All tests were two sided with a P-value,0.05 consid-
ered to be significant. The TIMI Study Group has an independent copy of
the trial database and conducted all analyses. Analyses were performed
with use of Stata/SE version 12.1 (Stata Corp., College Station, TX, USA).
Results
Baseline characteristics
At randomization, 2492 patients (11.8%) were receiving amiodarone.
Patients receiving amiodarone at baseline were equally distributed
among the three treatment arms (Table 1). As expected for a large
randomized clinical trial, baseline characteristics among patients on
amiodarone were very similar among the three treatment arms.
Patients on amiodarone at randomization who were assigned to war-
farin were more likely to be ≥75 years of age, but less likely to have
prior CHF or hypertension than patients assigned to edoxaban.
There were no significant differences between the three treatment
arms in patients without amiodarone at baseline (Supplementary
material online, Table S1).
Over the entire study cohort, patients on amiodarone at random-
ization were younger and overall had fewer comorbidities than
patients not receiving the drug, except for a higher prevalence of
coronary artery disease and congestive heart failure (Supplementary
material online, Table S2). Of note, patients on amiodarone were less
frequently in the INR target range when compared with those not on
the drug (% time in therapeutic range [INR 2.0–3.0]: 64.0% [inter-
quartile range, 52.4–73.2%] vs. 69.0% [interquartile range, 57.1–
77.9%], P, 0.001), likely secondary to drug–drug interaction
between amiodarone and warfarin.
Efficacy of edoxaban vs. warfarin in
amiodarone-treated patients
A significant interaction for amiodarone use vs. non-use was
observed for several efficacy endpoints in patients randomized to
LD edoxaban vs. warfarin (Figure. 1). There was significantly greater
relative efficacy with LD edoxaban compared with warfarin in
patients on amiodarone at baseline compared with those not on
amiodarone for the primary endpoint of stroke or SEE (HR 0.60,
95% CI 0.36–0.99 and HR 1.20, 95% CI 1.03–1.40 for amiodarone
and no amiodarone patients, respectively; P interaction ¼ 0.009),
and the pre-specified net clinical endpoints of death, stroke, SEE, or
J. Steffel et al.2240
major bleed (P interaction ¼ 0.016), and death, stroke, SEE, or life-
threatening bleed (P interaction ¼ 0.014). No significant interaction
with respect to amiodarone use at baseline was observed for HD
edoxaban.
As outlined above, baseline characteristics among patients on
amiodarone were very similar among the three treatment arms.
A sensitivity analysis was consistent after multivariable adjustment
for differences in baseline characteristics across randomized treat-
ment groups in patients taking amiodarone as outlined in Table 1
(age ≥75 years, heart failure, and hypertension), with interaction
P-values for stroke/SEE P ¼ 0.012 for the LD group and P ¼ 0.533
for the HD group. Indeed, two of these three variables in fact indicate
a potentially higher risk for stroke in the edoxaban arms when com-
pared with warfarin (higher percentage of patients with a history of
heart failure, and of patients with a history of hypertension).
Safety of edoxaban vs. warfarin in
amiodarone-treated patients
Lower-dose edoxabanandHD edoxaban significantly reduced major
bleeding by 53 and 20%, respectively, compared with warfarin.1 No
significant interaction by baseline amiodarone use was observed in
patients randomized to LD edoxaban for any bleeding outcome
(Figure. 2). For HD edoxaban, there was no interaction by baseline
amiodarone use for major bleeding but there was greater relative
major plus clinically relevant non-major bleeding compared with
warfarin in HD edoxaban patients on amiodarone at baseline (HR
1.12, 95% CI 0.91–1.36) vs. those who were not (HR 0.83, 95% CI
0.77–0.89; P interaction 0.008). There was no interaction by amio-
darone use at baseline in HD edoxaban patients with respect to
more severe bleeding outcomes such as intracranial haemorrhage,
life-threatening bleeding, or fatal bleeding.
A sensitivity analysis was consistent after multivariable adjustment
for differences inbaselinecharacteristics across randomizedtreatment
groups in patients taking amiodarone as outlined in Table 1 (age ≥75
years, heart failure, and hypertension), with interaction P-values for
major bleed P ¼ 0.161 and P ¼ 0.275 for the LD and HD group, re-
spectively. Indeed, two of these three variables in fact indicate a poten-
tially higher risk for bleeding in the edoxaban arms when compared
with warfarin (higher percentage of patients with a history of heart
failure, and of patients with a history of hypertension).
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Table 1 Baseline characteristics per randomization group of patients treated with amiodarone at baseline
Edo low dose (%)
N 5 799
Edo high dose (%)
N5 866
Warfarin (%)
N 5 827
P-value
Age (years) 69 (61–76) 68 (61–75) 69 (61–76) 0.081
Age ≥75 years 242 (30.3%) 235 (27.1%) 274 (33.1%) 0.027
Male gender 469 (58.7%) 548 (63.3%) 508 (61.4%) 0.157
Region 0.523
North American 100 (12.5%) 128 (14.8%) 111 (13.4%)
Latin American 173 (21.7%) 169 (19.5%) 178 (21.5%)
Western Europe 97 (12.1%) 119 (13.7%) 89 (10.8%)
Eastern Europe 333 (41.7%) 348 (40.2%) 338 (40.9%)
Asia, Japan and South Africa 96 (12%) 102 (11.8%) 111 (13.4%)
Type of afib 0.690
Paroxysmal 334 (41.8%) 338 (39%) 347 (42%)
Persistent 211 (26.4%) 244 (28.2%) 213 (25.8%)
Permanent 254 (31.8%) 284 (32.8%) 267 (32.3%)
CHADS2 score (mean) 2.7 (0.9) 2.8 (0.9) 2.8 (0.9) 0.169
CHADS2 score .3 154 (19.3%) 177 (20.4%) 170 (20.6%) 0.776
CrCl at randomization (mL/min) 70.0 (52.1–93.0) 69.4 (52.9–91.5) 69.5 (52.0–89.9) 0.666
History of stroke or TIA 191 (23.9%) 208 (24%) 210 (25.4%) 0.736
History of CHF 543 (68%) 630 (72.7%) 552 (66.7%) 0.018
History of diabetes 234 (29.3%) 285 (32.9%) 278 (33.6%) 0.134
History of hypertension 768 (96.1%) 837 (96.7%) 780 (94.3%) 0.047
Prior MI 110 (13.8%) 113 (13%) 93 (11.3%) 0.292
VKA naive 432 (54.1%) 428 (49.4%) 416 (50.3%) 0.136
Dose reduced at randomization
a
214 (26.8%) 218 (25.2%) 215 (26%) 0.755
Medication use at randomization
Aspirin 256 (32%) 290 (33.5%) 275 (33.3%) 0.800
Thienopyridine 26 (3.3%) 21 (2.4%) 20 (2.4%) 0.487
Digoxin or digitalis preparations 160 (20%) 179 (20.7%) 166 (20.1%) 0.935
Data are presented as medians (interquartile ranges) for continuous variables and frequencies for categorical variables.
aIn patients with an estimated creatinine clearance 30–50 mL/min, body weight≤60 kg, or in those requiring concomitant use of verapamil, quinidine, or dronedarone, the edoxaban
dose was reduced by 50% (HD edoxaban: 6030 mg; LD edoxaban 30 mg15 mg).
Edoxaban in patients on amiodarone 2241
Figure 1 Efficacy of edoxaban vs. warfarin in patients with and without amiodarone at baseline. Number of evens and event rates (%/year), as well as hazard ratios for higher-dose and lower-dose
edoxaban are shown for patients with (red, upper row) and without (black, lower row) amiodarone. A sensitivity analysis was consistent after multivariable adjustment for differences in baseline char-
acteristics across randomized treatment groups in patients taking amiodarone as outlined in Table 1 (age≥75 years, heart failure, and hypertension): Interaction P-values for stroke/SEE P ¼ 0.012 for the
lower-dose group and P ¼ 0.533 for the higher-dose group. CV, cardiovascular; EP, endpoint; MI, myocardial infarction; SEE, systemic symbolic event.
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Figure 2 Safety of edoxaban vs. warfarin in patients with and without amiodarone at baseline. Number of evens and event rates (%/year), as well as hazard ratios for higher-dose and lower-dose
edoxaban are shown for patients with (red, upper row) and without (black, lower row) amiodarone. A sensitivity analysis was consistent after multivariable adjustment for differences in baseline char-
acteristics across randomized treatment groups in patients taking amiodarone as outlined in Table 1 (age ≥75 years, heart failure, and hypertension): Interaction P-values for major bleed P ¼ 0.161 and
P ¼ 0.275 for the lower-dose and higher-dose group, respectively. CRNM, clinically relevant non-major; GI, gastrointestinal; ICH, intracranial haemorrhage. * No interaction P calculated as n ¼ 0 for
patients on lower-dose edoxaban and amiodarone.
Edoxaban
in
patients
on
am
iodarone
2243
Edoxaban drug levels
Edoxaban trough concentrations at 1 month post-randomization
were available in 6780 of the 14,069 patients randomized to edoxa-
ban. In both edoxaban regimens, amiodarone was associated with
significantly increased trough levels compared with patients not on
amiodarone: LD edoxaban: with amiodarone 27.3 ng/mL + 24.5
ng/mL vs. no amiodarone 21.9+ 20.8 ng/mL, P, 0.001; HD edoxa-
ban: with amiodarone 58.5+53.2 ng/mL vs. no amiodarone 43.2+
41.1 ng/mL, P, 0.001.
Discussion
Amiodarone is among the most frequently prescribed and effective
anti-arrhythmic drugs used in patients with AF.6 Although amiodar-
one use is complicated by its side effect profile, it is one of the only
anti-arrhythmics that can be used in the large proportion of patients
with structural heart disease, heart failure, and coronary artery
disease (in contrast to other anti-arrhythmics such as class Ic
agents or dronedarone, which are contraindicated in these patients).
Furthermore, only a negligible proportion of amiodarone is cleared
via the kidneys, making it an attractive treatment option in patients
with renal impairment, whereas dose adjustment is necessary with
other agents (e.g. propafenone and dofetilide). On the other hand,
amiodarone is known to interact with VKA, leading to more difficult
INR control, as demonstrated by our data.
In the current pre-specified subgroup analysis, patients rando-
mized to LD edoxaban who were taking amiodarone at baseline
had fewer ischaemic events compared with warfarin vs. patients
not on amiodarone. Importantly, the improved efficacy of LD edox-
aban in amiodarone treated patients did not result in an increase
in bleeding across the full range of severity. In contrast, the efficacy
of HD edoxaban compared with warfarin was similar in patients
treated with and without amiodarone at baseline. Although an
increase in clinically relevant non-major bleeds associated with con-
comitant amiodarone use in the HD edoxaban group was observed,
there was no effect on major or life-threatening bleeds.
Differential relative efficacy and safety
between high dose and low dose edoxaban
in amiodarone-treated patients
The increase in the relative efficacy of LD edoxaban compared with
warfarin in patients taking amiodarone is likely to be mediated by
the increased edoxaban concentration that was observed due to in-
hibition of P-gp by amiodarone. Interestingly, although concomitant
amiodarone also increased the concentration of HD edoxaban,
there was no corresponding increase in efficacy compared with war-
farin. Conversely, the increase in concentration in LD edoxaban
patients taking amiodarone did not result in an excess in any type
of bleeding compared with warfarin, while a similar increase in con-
centration in HD edoxaban patients resulted in an increase in clinic-
ally relevant non-majorbleeding (althoughnotmajorormoreserious
types of bleeding). What explains the differential efficacy and safety
between HD and LD edoxaban in amiodarone-treated patients? In
a previous analysis from ENGAGE AF-TIMI 48, we observed that
increased edoxaban concentration is inversely associated with the
risk of stroke or systemic embolism; the slope of the association,
however, was modest. In contrast, a much steeper association was
observed for major bleeding.7 Our current observations are in line
with this analysis. Increase in plasma levels caused by co-administration
of amiodarone in LD edoxaban patients occurs at an inflection point in
the dose–response curve for efficacy, resulting in a significant reduc-
tion in ischaemic events. At the same time, this increase in concentra-
tion still falls within the ‘flatter’ part of the dose–response curve for
bleeding. In contrast, the increase in concentration in HD edoxaban
patients taking amiodarone occurs during the ‘flat’ portion of the
dose–response curve for efficacy, resulting in no further increase in
the reduction of ischemic events. The increased concentration for
HD edoxaban does fall, however, on the steeper part of the dose–
response curve for bleeding.
Amiodarone co-treatment with other
non-vitamin K oral anti-coagulants
The oral direct thrombin inhibitor dabigatran, as well as the oral
factor Xa inhibitors rivaroxaban and apixaban have all demonstrated
non-inferior or superior efficacy for stroke prevention in AF when
compared with warfarin.9– 12 Dabigatran, rivaroxaban, and apixaban
all undergo P-gp-dependent metabolism, to varying degrees. Amio-
darone leads to plasma level increases in pharmacokinetic trials of
12–60% for dabigatran.13,14 Furthermore, amiodarone and its me-
tabolite are inhibitors of Cytochrome P450 (CYP 450) 3A4. While
rivaroxaban and apixaban are both metabolized by 32% by CYP
450 3A4, it is only marginally involved (,4%) in the metabolism of
edoxaban and dabigatran.15
As outlined above, we studied two dose regimens of edoxaban and
our findings suggest that the dose–response curve is not linear with
respect to prevention of stroke/SEE. A modest increase in edoxaban
drug levels in patients receiving amiodarone in the HD edoxaban
group did not appear to confer greater efficacy, likely because a
change at this end of the dose–concentration curve is not that im-
portant regarding efficacy. In contrast, the increase in edoxaban con-
centration in patients receiving amiodarone did confer greater
treatment effect, suggesting a steeper relationship between drug con-
centrationand protection fromstroke/SEE at the lower rangeof edox-
aban concentrations. We note that there was a similar directional
trend with low dose dabigatran 110 mg BID in RE-LY, but not with
the HD dabigatran.10,16 Our findings in ENGAGE AF-TIMI 48 may
have been even more apparent since the two dose regimens of edox-
aban differed by a factor of 2.0, where in RE-LY the two doses differed
by a factor of 1.36. Finally, there was only one dose regimen studied
with rivaroxaban and apixaban in ROCKET-AF and ARISTOTLE, re-
spectively. We speculate that these dose regimens are at the higher
end of the dose response (i.e. more similar to edoxaban HD and dabi-
gatran 150 BID) where a modest increase in FXa inhibition due to
amiodarone may not translate in an apparent clinical benefit.
Limitations
Although pre-specified, this subgroup analysis of the ENGAGE
AF-TIMI 48 should be interpreted as hypothesis generating. While
baseline parameters only differed slightly in three variables (percent-
age of patients .75 years, history of CHF, and history of hyperten-
sion), therapy with amiodarone was not randomized nor stratified
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leaving the possibility of unmeasured residual confounding and bias
through multiple testing. Although a biologically plausible explan-
ation of our study’s findings can be deducted from previous analyses
from ENGAGE AF-TIMI 48, a chance finding cannot be ruled out due
tomultiple testing and the sample sizeof the subgroup (2492patients,
11.8% of total study population). We used conventional significance
levels for testing interactions with large enough differences observed
in the magnitudes of the HRs for the primary efficacy endpoint bet-
ween the two groups. As always, results of subgroup analyses need
to be interpreted with caution in the context of power and type I
error. Furthermore, our analysis was limited to amiodarone use at ran-
domization and did not account for the amiodarone potentially being
discontinued or initiated during the course of the trial. However, ana-
lyzing and censoring outcome events upon discontinuation of amio-
darone would be subject to substantial flaws, including loss of
randomization by using a post-randomization variable as well as the in-
herentdifficulty topredict any residual effectofamiodaroneat the time
of a subsequent event in view of its long half-life (mean 60 days).
Conclusions
Patients randomized to the LD edoxaban regimen treated with
amiodarone at the time of randomization demonstrated a signifi-
cant reduction in ischaemic events vs. warfarin when compared
with those not on amiodarone, while preserving a favourable bleed-
ing profile. In contrast, no additional efficacy was observed in
amiodarone-treated patients randomized to HD edoxaban at a
cost of more clinically relevant non-major bleeding. These results
indicate that in patients of ENGAGE AF-TIMI 48 co-administered
with amiodarone, LD edoxaban achieves a ‘sweet spot’ between
protection from ischaemic events and bleeding.
Supplementary material
Supplementary material is available at European Heart Journal online.
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